Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2018
At a glance
- Drugs Cediranib (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 07 Jun 2018 Planned primary completion date changed from 31 Jul 2019 to 30 Sep 2018.
- 05 Jun 2018 Results (n=7) from stage I of the study, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 04 Apr 2018 Planned End Date changed from 31 Jul 2018 to 31 Jul 2019.